Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

ACAD

Acadia Pharmaceuticals Inc

Feb 10 • 04:00PM ET

22.70

-0.52 -2.24 %

Healthcare • Biotechnology • USA • NASD

Peers: NBIX BIIB VRTX INCY BMRN ALNY IONS REGN GILD AMGN

| Held by: IJR VTI XBI VB IWM FBT VBK VXF IBB SPSM

Index	RUT	P/E	14.60	EPS (ttm)	1.55	Insider Own	1.08%	Shs Outstand	169.15M	Perf Week	-8.32%
Market Cap	3.84B	Forward P/E	31.76	EPS next Y	0.71	Insider Trans	-4.11%	Shs Float	167.35M	Perf Month	-15.24%
Enterprise Value	3.05B	PEG	-	EPS next Q	0.13	Inst Own	100.07%	Short Float	5.57%	Perf Quarter	0.58%
Income	261.17M	P/S	3.67	EPS this Y	-39.88%	Inst Trans	-0.51%	Short Ratio	6.61	Perf Half Y	-8.54%
Sales	1.05B	P/B	4.19	EPS next Y	-12.58%	ROA	22.64%	Short Interest	9.31M	Perf YTD	-15.01%
Book/sh	5.42	P/C	4.53	EPS next 5Y	-7.12%	ROE	34.95%	52W High	28.35 -19.93%	Perf Year	20.23%
Cash/sh	5.01	P/FCF	19.41	EPS past 3/5Y	- -	ROIC	27.20%	52W Low	13.40 69.40%	Perf 3Y	19.66%
Dividend Est.	-	EV/EBITDA	28.10	Sales past 3/5Y	25.54% 23.08%	Gross Margin	91.92%	Volatility	3.33% 3.72%	Perf 5Y	-56.03%
Dividend TTM	-	EV/Sales	2.91	EPS Y/Y TTM	100.80%	Oper. Margin	9.02%	ATR (14)	0.91	Perf 10Y	24.52%
Dividend Ex-Date	-	Quick Ratio	2.94	Sales Y/Y TTM	12.69%	Profit Margin	24.94%	RSI (14)	29.39	Recom	1.85
Dividend Gr. 3/5Y	- -	Current Ratio	3.02	EPS Q/Q	113.29%	SMA20	-11.12%	Beta	0.67	Target Price	31.21
Payout	0.00%	Debt/Eq	0.06	Sales Q/Q	11.27%	SMA50	-13.63%	Rel Volume	0.79	Prev Close	23.22
Employees	654	LT Debt/Eq	0.05	Earnings	Feb 25 AMC	SMA200	-2.14%	Avg Volume	1.41M	Price	22.70
IPO	May 27, 2004	Option/Short	Yes / Yes	EPS/Sales Surpr.	142.91% 0.76%	Trades		Volume	1,108,962	Change	-2.24%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-21-25	Initiated	Citigroup	Buy	$33
May-21-25	Upgrade	Deutsche Bank	Hold → Buy	$35
Feb-11-25	Initiated	Deutsche Bank	Hold	$22
Jan-03-25	Downgrade	Guggenheim	Buy → Neutral	$23 → $20
Oct-10-24	Resumed	Raymond James	Mkt Perform
Aug-07-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$28 → $20
Jun-27-24	Initiated	BMO Capital Markets	Outperform	$31
Mar-12-24	Reiterated	Needham	Buy	$36 → $32
Mar-12-24	Downgrade	Mizuho	Buy → Neutral	$39 → $25
Jan-30-24	Initiated	Robert W. Baird	Outperform	$40
Jan-24-24	Upgrade	Needham	Hold → Buy	$37
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$31 → $40
Dec-14-23	Downgrade	Deutsche Bank	Buy → Hold	$25
Dec-13-23	Initiated	Citigroup	Buy	$38
Dec-12-23	Initiated	Deutsche Bank	Buy	$25
Nov-06-23	Upgrade	Mizuho	Neutral → Buy	$20 → $35
Oct-17-23	Initiated	UBS	Buy	$33
Oct-10-23	Upgrade	JP Morgan	Neutral → Overweight	$29 → $32
Jan-03-23	Upgrade	Guggenheim	Neutral → Buy	$22
Nov-04-22	Downgrade	Goldman	Neutral → Sell	$15 → $12

Show Previous Ratings

Feb-04-26 04:05PM	Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 (Business Wire)
Feb-03-26 12:44PM	EU Panel Rejects Acadia Pharmaceuticals Rett Syndrome Drug (Benzinga) -5.24%
10:00AM	5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates (Zacks)
07:52AM	Acadia Expects Negative CHMP Opinion for Rett Syndrome Drug in EU (Zacks)
05:11AM	FDA launches PreCheck program; AstraZeneca, Acadia drugs set back (BioPharma Dive)
04:05PM	Loading…
Feb-02-26 04:05PM	Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union (Business Wire)
12:10PM	Why Acadia (ACAD) is Poised to Beat Earnings Estimates Again (Zacks)
Jan-28-26 11:40AM	FTRE or ACAD: Which Is the Better Value Stock Right Now? (Zacks)
Jan-26-26 10:15AM	Auvelity Continues to Aid AXSM's Top Line: More Upside in 2026? (Zacks)
Jan-13-26 02:06PM	ACADIA Pharmaceuticals Targets $1.7B Sales by 2028, Maps Key Remlifansirin Readouts at JPM Conf (MarketBeat)
09:00AM	Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Jan-12-26 04:01PM	Acadia Pharmaceuticals Focuses on Next-Gen Neuroscience (Bloomberg)
11:40AM	FTRE vs. ACAD: Which Stock Is the Better Value Option? (Zacks)
Dec-22-25 09:50AM	Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock (Zacks)
Dec-18-25 04:05PM	Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 (Business Wire)
08:00AM	Loading…
Dec-12-25 08:00AM	Acadia Pharmaceuticals Announces FDA Approval of DAYBUE STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome (Business Wire)
Dec-11-25 04:27PM	Rhythm Pharma Hits Record High On Unexpected Obesity-Tied Win (Investor's Business Daily)
Dec-10-25 11:30AM	Why Is CRISPR Therapeutics (CRSP) Up 3.3% Since Last Earnings Report? (Zacks)
Dec-05-25 11:30AM	Why Is Acadia (ACAD) Up 22.6% Since Last Earnings Report? (Zacks)
Dec-03-25 09:17AM	Acadia to pivot to Alzheimers psychosis pipeline, accd to Wall Street analysts (Investing.com)
Nov-28-25 09:50AM	Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock (Zacks)
Nov-20-25 04:05PM	Acadia Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference (Business Wire)
Nov-12-25 09:50AM	Why Acadia Pharmaceuticals (ACAD) is a Top Momentum Stock for the Long-Term (Zacks)
Nov-07-25 10:11AM	Nektar Therapeutics Q3 Loss Narrower Than Expected, Revenues Rise Y/Y (Zacks)
09:56AM	Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble (Zacks)
Nov-06-25 11:23AM	ACAD Q3 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth (Zacks)
10:43AM	Catalyst Pharmaceuticals Q3 Earnings Beat, Firdapse Revenues Rise Y/Y (Zacks)
09:24AM	RXRX Q3 Loss Narrower Than Expected, Revenues Decline Y/Y (Zacks)
12:00AM	ACADIA Pharmaceuticals Inc (ACAD) Q3 2025 Earnings Call Highlights: Record Sales and Strategic ... (GuruFocus.com)
Nov-05-25 05:20PM	Acadia Pharmaceuticals (ACAD) Q3 Earnings and Revenues Top Estimates (Zacks)
04:18PM	Loading…
04:18PM	Acadia: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview (Business Wire)
12:04PM	Waters Q3 Earnings Surpass Estimates, Revenue Increase Y/Y (Zacks)
Oct-29-25 10:00AM	Analysts Estimate Acadia Pharmaceuticals (ACAD) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-28-25 04:05PM	Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences (Business Wire)
12:00PM	Acadia (ACAD) Moves to Buy: Rationale Behind the Upgrade (Zacks)
09:55AM	Does Acadia (ACAD) Have the Potential to Rally 27.66% as Wall Street Analysts Expect? (Zacks)
09:40AM	Is HCA HEALTHCARE (HCA) Stock Outpacing Its Medical Peers This Year? (Zacks)
Oct-22-25 03:41PM	Halper Sadeh LLC Encourages Acadia Pharmaceuticals Inc. Shareholders to Contact the Firm to Discuss Their Rights (Business Wire)
Oct-21-25 09:20AM	Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions (PR Newswire)
Oct-15-25 04:05PM	Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025 (Business Wire) +6.78% -5.15%
Oct-09-25 11:40AM	QGEN vs. ACAD: Which Stock Is the Better Value Option? (Zacks)
Oct-02-25 09:04AM	Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson's Disease and Movement Disorders (Business Wire)
Sep-30-25 09:45AM	Can Auvelity Drive Axsome's Growth Through the Rest of 2025? (Zacks)
Sep-25-25 10:50AM	ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure (Zacks)
Sep-24-25 04:20PM	Acadia Pharma Tumbles On Failed Genetic Disease Drug; Soleno Surges (Investor's Business Daily) -9.92%
09:32AM	Acadia Pharma Tumbles On Failed Appetite Suppressant; Soleno Surges (Investor's Business Daily)
09:27AM	Lithium Americas, Oracle, Acadia Pharma: Trending Tickers (Yahoo Finance Video)
07:28AM	Acadia to scrap Prader-Willi drug after study setback (BioPharma Dive)
07:00AM	Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint (Business Wire)
02:12AM	ACADIA Pharmaceuticals (ACAD) Announces Interim Results From LOTUS study on DAYBUE (Insider Monkey)
Sep-12-25 04:05PM	Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE (trofinetide) in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology (Business Wire)
Sep-11-25 11:13AM	ACADIA Pharmaceuticals Inc. (ACAD) Nears Key Phase 3 Readout in Prader-Willi Syndrome (Insider Monkey)
Sep-08-25 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-29-25 12:27PM	Axsome Shares Up 20% in a Month: How Should You Play the Stock? (Zacks)
04:53AM	ACADIA Pharmaceuticals Inc. (ACAD) Nears Phase 3 Readout in Prader-Willi Syndrome Trial (Insider Monkey)
Aug-26-25 04:05PM	Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences (Business Wire)
Aug-25-25 04:05PM	Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer (Business Wire)
Aug-21-25 09:49AM	JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug (Zacks)
Aug-11-25 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-07-25 10:04AM	Acadia Q2 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth (Zacks)
Aug-06-25 05:15PM	Acadia Pharmaceuticals (ACAD) Tops Q2 Earnings and Revenue Estimates (Zacks)
04:19PM	Acadia: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview (Business Wire)
Aug-05-25 06:00PM	Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
04:05PM	Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference (Business Wire)
09:32AM	Catalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards? (Zacks)
Aug-04-25 04:05PM	Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer (Business Wire)
12:23PM	Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards? (Zacks)
11:07AM	Sarepta to Report Q2 Earnings: What's in Store for the Stock? (Zacks)
Aug-01-25 11:40AM	GMAB vs. ACAD: Which Stock Is the Better Value Option? (Zacks)
Jul-30-25 10:00AM	Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Jul-23-25 04:05PM	Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2025 (Business Wire)
Jul-10-25 08:00AM	Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity (Investor's Business Daily)
Jul-04-25 11:40AM	KMDA or ACAD: Which Is the Better Value Stock Right Now? (Zacks)
Jul-03-25 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-26-25 08:23AM	Acadias very bullish sales forecast restores some confidence on Wall Street (BioPharma Dive)
Jun-25-25 08:00AM	Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers (Business Wire)
Jun-24-25 01:05PM	Acadia Pharmaceuticals price target raised to $38 from $26 at RBC Capital (TipRanks)
Jun-18-25 11:40AM	KMDA vs. ACAD: Which Stock Is the Better Value Option? (Zacks)
Jun-17-25 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-11-25 07:40PM	US Appeals Court Confirms Patent Validity of Acadia's Parkinson's Medication (Insider Monkey)
Jun-09-25 04:01PM	U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID (pimavanserin) Composition of Matter Patent (Business Wire)
Jun-06-25 11:31AM	Why Is Acadia (ACAD) Up 26.1% Since Last Earnings Report? (Zacks)
Jun-05-25 09:05AM	Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025 (Business Wire)
May-29-25 04:05PM	Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference (Business Wire)
May-27-25 04:05PM	Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise (Business Wire)
May-20-25 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
12:52PM	Why ACADIA Pharmaceuticals Inc. (ACAD) Skyrocketed on Friday (Insider Monkey)
10:55AM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
May-19-25 03:07PM	ACADIA Pharmaceuticals Stock Sees RS Rating Jump To 93 (Investor's Business Daily)
11:40AM	GSK or ACAD: Which Is the Better Value Stock Right Now? (Zacks)
09:32AM	ACAD Stock Soars as US Court Rules in Favor of Key Nuplazid Patent (Zacks)
May-17-25 01:36PM	Acadia Pharmaceuticals price target raised to $19 from $17 at Oppenheimer (TipRanks)
01:36PM	Acadia Nuplazid patent ruling removes key overhang, says BMO Capital (TipRanks)
May-16-25 01:43PM	Delaware District Court Rules in Favor of Acadia in NUPLAZID (pimavanserin) Formulation Patent Litigation (Business Wire) +26.48%
May-09-25 06:26PM	Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Revised) (Zacks)
May-08-25 10:40AM	Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth (Zacks) +14.31%
08:03AM	Q1 2025 ACADIA Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
03:28AM	ACADIA Pharmaceuticals Inc (ACAD) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rhodes Jennifer J	EVP, CHIEF LEGAL OFFICER, SEC	Feb 06 '26	Option Exercise	0.00	12,944	0	14,559	Feb 10 06:00 PM
Rhodes Jennifer J	EVP, CHIEF LEGAL OFFICER, SEC	Feb 09 '26	Sale	23.38	6,950	162,491	7,609	Feb 10 06:00 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Nov 18 '25	Sale	23.69	10,262	243,114	53,338	Nov 19 06:00 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	Nov 18 '25	Sale	23.69	4,084	96,754	25,058	Nov 19 06:00 PM
Daly James M	Director	Nov 10 '25	Sale	22.37	30,000	670,983	4,041	Nov 12 06:00 PM
James M Daly	Director	Nov 10 '25	Proposed Sale	22.37	30,000	670,983		Nov 10 05:59 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Sep 15 '25	Sale	23.65	3,498	82,728	43,447	Sep 16 06:00 PM
GAROFALO ELIZABETH A.	Director	Sep 02 '25	Sale	25.98	1,600	41,560	25,382	Sep 03 06:00 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Aug 18 '25	Sale	25.18	22,000	554,024	40,130	Aug 19 06:00 PM
Schneyer Mark C.	Officer	Aug 18 '25	Proposed Sale	25.33	22,000	557,260		Aug 18 04:31 PM
Brege Laura	Director	Jun 04 '25	Sale	21.78	14,446	314,634	15,095	Jun 05 06:01 PM
LAURA BREGE	Director	Jun 04 '25	Proposed Sale	21.78	14,446	314,638		Jun 04 04:35 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	May 16 '25	Sale	22.50	4,000	90,000	20,395	May 19 08:52 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	May 16 '25	Sale	25.00	2,000	50,000	62,130	May 19 08:50 PM
Schneyer Mark C.	Officer	May 16 '25	Proposed Sale	17.60	2,000	35,200		May 16 05:10 PM
Kihara James	Officer	May 16 '25	Proposed Sale	17.60	4,000	70,400		May 16 05:06 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	May 02 '25	Sale	14.60	1,327	19,374	23,526	May 02 08:00 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	May 02 '25	Sale	14.60	3,498	51,071	62,773	May 02 07:59 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Apr 08 '25	Sale	14.82	2,708	40,133	59,456	Apr 08 07:40 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	Apr 08 '25	Sale	14.82	1,028	15,235	22,257	Apr 08 07:38 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	Mar 26 '25	Sale	17.05	1,095	18,670	21,275	Mar 26 08:10 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Mar 26 '25	Sale	17.05	3,171	54,066	56,889	Mar 26 08:06 PM
GAROFALO ELIZABETH A.	Director	Mar 05 '25	Sale	18.23	4,919	89,673	17,595	Mar 06 06:30 PM
GAROFALO ELIZABETH A.	Director	Mar 05 '25	Proposed Sale	18.23	4,919	89,673		Mar 06 12:17 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	Feb 24 '25	Sale	19.96	475	9,481	20,228	Feb 25 06:48 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Feb 24 '25	Sale	19.96	773	15,429	53,882	Feb 25 06:46 PM

Open in Screener

MDGL

Madrigal Pharmaceuticals Inc

Feb 10 • 04:00PM ET

478.83

-9.43 -1.93 %

Healthcare • Biotechnology • USA • NASD

MDGL Madrigal Pharmaceuticals Inc daily Stock Chart

Peers: GILD AKRO VKTX NBIX ENTA SLDB LXRX TSHA NBP RDHL

| Held by: VTI VB IWM VXF XBI VBR IWO IBB VBK VTWO

Index	RUT	P/E	-	EPS (ttm)	-13.01	Insider Own	9.35%	Shs Outstand	22.70M	Perf Week	-0.75%
Market Cap	10.87B	Forward P/E	1231.37	EPS next Y	0.39	Insider Trans	-8.98%	Shs Float	20.59M	Perf Month	-6.85%
Enterprise Value	10.11B	PEG	-	EPS next Q	-0.81	Inst Own	103.08%	Short Float	19.35%	Perf Quarter	-2.13%
Income	-289.12M	P/S	14.68	EPS this Y	50.01%	Inst Trans	0.51%	Short Ratio	11.99	Perf Half Y	37.00%
Sales	740.64M	P/B	17.37	EPS next Y	103.55%	ROA	-23.74%	Short Interest	3.98M	Perf YTD	-17.77%
Book/sh	27.56	P/C	9.76	EPS next 5Y	-	ROE	-41.22%	52W High	615.00 -22.14%	Perf Year	41.85%
Cash/sh	49.08	P/FCF	-	EPS past 3/5Y	-14.40% -32.06%	ROIC	-29.77%	52W Low	265.00 80.69%	Perf 3Y	85.97%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	95.06%	Volatility	4.25% 3.95%	Perf 5Y	290.34%
Dividend TTM	-	EV/Sales	13.65	EPS Y/Y TTM	48.12%	Oper. Margin	-41.52%	ATR (14)	20.53	Perf 10Y	7100.45%
Dividend Ex-Date	-	Quick Ratio	3.26	Sales Y/Y TTM	864.21%	Profit Margin	-39.04%	RSI (14)	39.20	Recom	1.42
Dividend Gr. 3/5Y	- -	Current Ratio	3.44	EPS Q/Q	-3.26%	SMA20	-2.44%	Beta	-1.01	Target Price	656.25
Payout	-	Debt/Eq	0.55	Sales Q/Q	362.03%	SMA50	-11.22%	Rel Volume	1.30	Prev Close	488.26
Employees	528	LT Debt/Eq	0.55	Earnings	Feb 19 BMO	SMA200	14.82%	Avg Volume	332.29K	Price	478.83
IPO	Feb 06, 2007	Option/Short	Yes / Yes	EPS/Sales Surpr.	-122.31% 16.14%	Trades		Volume	432,158	Change	-1.93%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-28-26	Initiated	Barclays	Overweight	$964
Jan-06-26	Downgrade	Wolfe Research	Outperform → Peer Perform
Nov-05-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Nov-03-25	Upgrade	BofA Securities	Underperform → Neutral	$445
Oct-15-25	Initiated	Truist	Buy	$580
Sep-04-25	Resumed	H.C. Wainwright	Buy	$500
Feb-28-25	Upgrade	B. Riley Securities	Neutral → Buy	$236 → $422
Feb-27-25	Reiterated	H.C. Wainwright	Buy	$400 → $405
Jun-28-24	Initiated	Cantor Fitzgerald	Neutral
Jun-11-24	Initiated	Wolfe Research	Outperform	$382
Apr-22-24	Initiated	BofA Securities	Underperform	$150
Mar-15-24	Upgrade	B. Riley Securities	Sell → Neutral	$155 → $270
Mar-06-24	Initiated	Citigroup	Buy	$382
Feb-26-24	Downgrade	B. Riley Securities	Neutral → Sell	$155
Dec-20-22	Reiterated	Oppenheimer	Outperform	$170 → $250
Dec-19-22	Upgrade	Raymond James	Underperform → Mkt Perform
Dec-19-22	Reiterated	Piper Sandler	Overweight	$203 → $280
Dec-19-22	Reiterated	H.C. Wainwright	Buy	$170 → $225
Jul-08-22	Downgrade	B. Riley Securities	Buy → Neutral	$131 → $75
Oct-07-21	Initiated	Jefferies	Buy	$151

Show Previous Ratings

Feb-05-26 04:05PM	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-02-26 08:05AM	Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026 (GlobeNewswire)
Jan-31-26 08:15AM	Insiders Are Still Scooping Up Under Armour and WR Berkley Shares (24/7 Wall St.)
Jan-26-26 11:40AM	STVN or MDGL: Which Is the Better Value Stock Right Now? (Zacks)
Jan-25-26 05:30AM	Can Trump and Big Pharma Get the World to Pay More for Drugs? (The Wall Street Journal)
04:05PM	Loading…
Jan-22-26 04:05PM	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-21-26 04:05PM	Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-13-26 07:25PM	JPM26: Madrigal seeks early dominance in MASH through strategic acquisitions (Pharmaceutical Technology)
Jan-12-26 11:20AM	MDGL Secures Exclusive Global Right for MASH Treatment From PFE (Zacks)
Jan-11-26 12:01PM	Roblox, First Solar, And League Enterprise Are Among Top 10 Large Cap Losers Last Week (Jan. 5-Jan. 9): Are the Others in Your Portfolio? (Benzinga)
Jan-09-26 08:00AM	Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor (GlobeNewswire) -7.58%
06:28AM	Insmeds ginormous lung drug sales; J&Js US pricing deal (BioPharma Dive)
Jan-08-26 11:40AM	UTHR or MDGL: Which Is the Better Value Stock Right Now? (Zacks)
Jan-06-26 07:14PM	Why Madrigal Pharmaceuticals Stock Slumped on Tuesday (Motley Fool) -5.16%
Jan-05-26 05:05PM	Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead (Motley Fool)
01:43PM	Loading…
Jan-03-26 01:43PM	2 Tailwinds Behind Novo Nordisk Stock Heading Into 2026 (Motley Fool)
Jan-02-26 01:29PM	Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize (PR Newswire)
Dec-18-25 04:05PM	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.56%
Dec-15-25 04:05PM	Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-14-25 09:50AM	2 Predictions for Novo Nordisk in 2026 (Motley Fool)
Dec-11-25 07:44AM	H.C. Wainwright Keeps Buy on Madrigal Pharmaceuticals (MDGL) on Strong Rezdiffra Uptake and F2/F3 MASH Patient Data (Insider Monkey)
Dec-09-25 05:25PM	2 Stocks Up Over 600% in the Past 3 Years With More Room to Run (Motley Fool)
Dec-04-25 04:05PM	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
11:30AM	Madrigal (MDGL) Up 21.9% Since Last Earnings Report: Can It Continue? (Zacks)
Dec-01-25 07:58AM	Madrigal Pharmaceuticals (MDGL) Surged Following the Strong Launch and Execution of New Drug (Insider Monkey)
Nov-20-25 04:05PM	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-19-25 03:00AM	As Madrigal faces MASH rivals, keeping patients is as critical as finding new ones (Pharma Voice)
Nov-18-25 07:31AM	Do You Believe in the Upside Potential of Madrigal Pharmaceuticals (MDGL)? (Insider Monkey)
Nov-17-25 08:00AM	Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences (GlobeNewswire)
Nov-14-25 05:05PM	John Paulson's Strategic Move: Significant Increase in Bausch Health Companies Inc. (GuruFocus.com)
08:00AM	Loading…
Nov-10-25 08:00AM	Madrigal Presents New Data Demonstrating Rezdiffra (resmetirom) Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated MASH Cirrhosis (GlobeNewswire)
Nov-06-25 04:05PM	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-05-25 10:41AM	Madrigal Q3 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Up (Zacks) +7.02%
06:26AM	Soleno slumps despite sales uptick; Madrigals MASH drug continues ascent (BioPharma Dive)
Nov-04-25 04:02PM	Madrigal Pharmaceuticals Inc (MDGL) Q3 2025 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com) +7.83%
08:20AM	Madrigal (MDGL) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:19AM	Madrigal: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire)
Oct-29-25 10:00AM	Analysts Estimate electroCore, Inc. (ECOR) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-28-25 10:00AM	Madrigal (MDGL) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
08:00AM	Madrigal to Present New Data from the Company's MASH Program at AASLD's The Liver Meeting 2025 (GlobeNewswire)
Oct-22-25 08:00AM	Madrigal Pharmaceuticals to Release Third-Quarter 2025 Financial Results and Host Webcast on November 4, 2025 (GlobeNewswire)
Oct-21-25 04:05PM	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-10-25 08:59AM	Aquestive Therapeutics (AQST) Surges 7.9%: Is This an Indication of Further Gains? (Zacks)
Oct-07-25 04:05PM	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-18-25 04:05PM	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.59%
Sep-13-25 07:00AM	MarketBeat Week in Review - 09/08 - 09/12 (MarketBeat)
Sep-10-25 07:31AM	CoreWeave and Madrigal's Insider Trades Flash Bullish Signals (MarketBeat)
Sep-04-25 04:05PM	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
01:14PM	TD Cowen Sees Greater Upside in Madrigal (MDGL) Following Recent Rezdiffra Approval (Insider Monkey)
Sep-03-25 08:00AM	Madrigal Pharmaceuticals to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference (GlobeNewswire)
Aug-28-25 11:49PM	Leerink Partners Maintains a Buy on Madrigal Pharmaceuticals (MDGL), Here's Why (Insider Monkey)
08:00AM	Novo Nordisk Eyes New Arena Amid Weight-Loss Market Pressure (Investor's Business Daily)
Aug-25-25 09:01AM	Do You Believe in the Upside Potential of Madrigal Pharmaceuticals (MDGL)? (Insider Monkey)
Aug-21-25 04:05PM	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-20-25 12:45PM	Madrigal Gets Conditional Nod for MASH Drug Rezdiffra in EU (Zacks)
Aug-19-25 04:05PM	Madrigal Receives European Commission Approval for Rezdiffra (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis (GlobeNewswire)
Aug-18-25 04:08PM	Novo Nordisk Rallied On Wegovy's Newest Approval. But This Rival Rallied More. (Investor's Business Daily) +5.84%
09:34AM	Novo Nordisk Pops On A New Wegovy Approval, Dragging Hard On Madrigal Pharma (Investor's Business Daily)
08:05AM	Madrigal stock falls after Novo Nordisks Wegovy wins FDA approval for MASH (Investing.com)
Aug-15-25 11:05AM	John Paulson's Strategic Moves: A Closer Look at Perpetua Resources Corp (GuruFocus.com)
Aug-12-25 09:00AM	Credo AI Launches Advisory Services to Make Trusted AI Governance Real, Auditable, and Measurable (Business Wire)
Aug-11-25 08:00AM	Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference (GlobeNewswire)
Aug-08-25 06:35PM	Madrigal Pharmaceuticals CEO: We're positioned for decades of growth (CNBC TV)
Aug-07-25 04:05PM	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-06-25 07:30AM	Nxera debuts an obesity pipeline; BridgeBio battles Alnylam for market share (BioPharma Dive)
Aug-05-25 08:15AM	Madrigal (MDGL) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +8.59%
07:11AM	Madrigal: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire)
Jul-30-25 08:30AM	Madrigal buys into GLP-1 from CSPC; Apellis wins expanded drug approval (BioPharma Dive)
05:00AM	Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited (GlobeNewswire)
Jul-25-25 10:42PM	Madrigal Pharmaceuticals, Inc. (MDGL)'s Rezdiffra Hits 51% Liver Stiffness Reduction in Phase 3 (Insider Monkey)
08:00AM	Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025 (GlobeNewswire)
Jul-24-25 11:47PM	Madrigal (MDGL) Secures $500M to Fuel MASH Pipeline Expansion (Insider Monkey)
Jul-22-25 08:00AM	Madrigal Pharmaceuticals Secures $500 Million in Senior Secured Credit from Blue Owl Managed Funds to Further Extend Leadership Position in MASH (GlobeNewswire) -5.30%
Jul-17-25 11:34AM	MDGL Stock Soars 11% on New Patent Protecting Rezdiffra Dosing Rights (Zacks)
07:10AM	Madrigal (MDGL) Moves 10.9% Higher: Will This Strength Last? (Zacks)
Jul-16-25 04:05PM	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.87%
08:00AM	Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra (Resmetirom) (GlobeNewswire)
Jul-02-25 02:46AM	JMP Reaffirms Price Target for Madrigal Amid Rezdiffra Growth Potential (Insider Monkey)
Jun-24-25 12:45PM	Madrigal Pharmaceuticals Closer to EU Approval for First MASH Treatment, Rezdiffra (Insider Monkey)
Jun-20-25 12:04PM	Madrigal poised to enter European MASH market after CHMP endorsement (Pharmaceutical Technology)
06:30AM	Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis (GlobeNewswire)
Jun-17-25 04:05PM	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-02-25 08:00AM	Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference (GlobeNewswire)
May-26-25 11:15AM	Short Report: Bears bite into Krispy Kreme after another weak earnings report (TipRanks)
May-15-25 07:21PM	John Paulson's Strategic Move: Honeywell International Inc. Takes Center Stage (GuruFocus.com)
May-13-25 09:45AM	2 Monster Stocks in the Making to Buy Now and Hold for 10 Years (Motley Fool)
May-10-25 07:15AM	Madrigal Announces New Clinical Data Demonstrating Rezdiffra (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis (GlobeNewswire)
May-08-25 11:41PM	Madrigal Pharmaceuticals, Inc. (MDGL): Among Nicholas J. Pritzker's Stock Picks with Huge Upside Potential (Insider Monkey)
May-07-25 08:47AM	Madrigal Pharmaceuticals (MDGL): Among Billionaire John Paulson's Stocks with Huge Upside Potential (Insider Monkey)
May-02-25 03:02AM	Madrigal Pharmaceuticals Inc (MDGL) Q1 2025 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com)
May-01-25 10:57PM	Q1 2025 Madrigal Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
01:01PM	Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2025 Earnings Call Transcript (Seeking Alpha)
10:40AM	Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up (Zacks)
08:20AM	Madrigal (MDGL) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:17AM	Madrigal: Q1 Earnings Snapshot (Associated Press Finance)
07:17AM	Madrigals MASH drug sales again top Wall Street projections (BioPharma Dive)
07:00AM	Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire)
Apr-29-25 08:00AM	Madrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL Congress (GlobeNewswire)

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Levy Richard S	Director	Jan 26 '26	Option Exercise	16.46	4,000	65,840	25,197	Jan 26 06:02 PM
Huntsman Carole	Chief Commercial Officer	Jan 26 '26	Sale	493.78	910	449,339	9,122	Jan 26 05:38 PM
Carole Huntsman	Officer	Jan 26 '26	Proposed Sale	480.45	340	163,353		Jan 26 05:35 PM
Sibold William John	President and CEO	Jan 26 '26	Sale	492.42	1,577	776,546	148,497	Jan 26 05:14 PM
William Sibold	Officer and Director	Jan 26 '26	Proposed Sale	480.45	1,577	757,670		Jan 26 05:11 PM
Taub Rebecca	Director	Jan 26 '26	Sale	492.42	647	318,596	452,704	Jan 26 05:05 PM
Rebecca Taub	Director	Jan 26 '26	Proposed Sale	480.45	647	310,851		Jan 26 05:02 PM
CAROLE A HUNTSMAN	Officer	Jan 26 '26	Proposed Sale	480.45	570	273,856		Jan 26 04:31 PM
Kelley Shannon T	General Counsel	Jan 20 '26	Sale	497.36	692	344,173	8,481	Jan 20 05:58 PM
Shannon Kelley	Officer	Jan 20 '26	Proposed Sale	501.68	263	131,942		Jan 20 05:54 PM
Taub Rebecca	Director	Jan 20 '26	Sale	490.77	2,238	1,098,343	453,351	Jan 20 05:46 PM
Rebecca Taub	Director	Jan 20 '26	Proposed Sale	501.68	2,238	1,122,760		Jan 20 05:38 PM
SHANNON KELLEY	Officer	Jan 20 '26	Proposed Sale	501.68	429	215,221		Jan 20 04:39 PM
FRIEDMAN PAUL A	Director	Jan 09 '26	Option Exercise	15.80	280	4,424	187,444	Jan 13 04:47 PM
FRIEDMAN PAUL A	Director	Jan 09 '26	Sale	551.24	280	154,348	187,164	Jan 13 04:47 PM
FRIEDMAN PAUL A	Director	Jan 09 '26	Option Exercise	15.80	24,520	387,416	211,684	Jan 13 04:43 PM
FRIEDMAN PAUL A	Director	Jan 09 '26	Sale	522.39	24,520	12,808,957	187,164	Jan 13 04:43 PM
Taub Rebecca	Director	Jan 09 '26	Option Exercise	15.80	240	3,792	455,829	Jan 13 04:38 PM
Taub Rebecca	Director	Jan 09 '26	Sale	550.33	240	132,080	455,589	Jan 13 04:38 PM
Taub Rebecca	Director	Jan 09 '26	Option Exercise	15.80	18,410	290,878	473,999	Jan 13 04:34 PM
Taub Rebecca	Director	Jan 09 '26	Sale	522.40	18,410	9,617,312	455,589	Jan 13 04:34 PM
REBECCA A TAUB	Director	Jan 09 '26	Proposed Sale	556.22	18,650	10,373,503		Jan 09 04:30 PM
FRIEDMAN PAUL A	Director	Dec 10 '25	Option Exercise	15.80	24,800	391,840	211,964	Dec 12 04:40 PM
FRIEDMAN PAUL A	Director	Dec 10 '25	Sale	552.18	24,800	13,694,158	187,164	Dec 12 04:40 PM
Taub Rebecca	Director	Dec 10 '25	Option Exercise	15.80	18,650	294,670	479,694	Dec 12 04:35 PM
Taub Rebecca	Director	Dec 10 '25	Sale	552.15	18,650	10,297,573	461,044	Dec 12 04:35 PM
PAUL FRIEDMAN	Director	Dec 10 '25	Proposed Sale	553.92	49,600	27,474,432		Dec 10 04:17 PM
REBECCA A TAUB	Director	Dec 10 '25	Proposed Sale	553.92	18,650	10,330,608		Dec 10 04:17 PM
Sibold William John	President and CEO	Dec 04 '25	Sale	575.34	2,400	1,380,816	150,074	Dec 04 05:26 PM
William John Sibold	Officer and Director	Dec 04 '25	Proposed Sale	579.89	2,400	1,391,736		Dec 04 05:06 PM
Dier Mardi	EVP and CFO	Dec 02 '25	Option Exercise	251.63	4,173	1,050,052	14,613	Dec 03 05:59 PM
Dier Mardi	EVP and CFO	Dec 02 '25	Sale	578.34	4,173	2,413,416	10,440	Dec 03 05:59 PM
MARDI C DIER	Officer	Dec 02 '25	Proposed Sale	579.45	4,173	2,418,045		Dec 02 04:23 PM
Huntsman Carole	Chief Commercial Officer	Nov 21 '25	Sale	553.11	1,958	1,082,986	10,032	Nov 21 05:39 PM
Carole Huntsman	Officer	Nov 21 '25	Proposed Sale	542.12	894	484,655		Nov 21 04:26 PM
Levy Richard S	Director	Nov 13 '25	Option Exercise	13.78	8,500	117,160	29,697	Nov 14 05:12 PM
Levy Richard S	Director	Nov 13 '25	Sale	520.96	8,500	4,428,198	21,197	Nov 14 05:12 PM
RICHARD S LEVY	Director	Nov 13 '25	Proposed Sale	528.94	8,500	4,495,990		Nov 13 04:26 PM
BATE KENNETH	Director	Nov 05 '25	Option Exercise	205.07	16,575	3,399,036	19,202	Nov 07 04:20 PM
BATE KENNETH	Director	Nov 05 '25	Sale	484.30	16,575	8,027,354	2,627	Nov 07 04:20 PM
KENNETH M BATE	Director	Nov 05 '25	Proposed Sale	484.30	16,575	8,027,354		Nov 05 04:15 PM
William John Sibold	Officer and Director	Sep 09 '25	Proposed Sale	453.80	7,279	3,303,210		Sep 09 09:24 PM
Sibold William John	President and CEO	Sep 09 '25	Sale	445.63	7,279	3,243,741	102,474	Sep 09 09:07 PM
FRED CRAVES	Former Director	Aug 29 '25	Proposed Sale	431.69	2,900	1,251,896		Aug 29 04:06 PM
Sibold William John	President and CEO	Aug 21 '25	Sale	400.18	7,616	3,047,756	109,753	Aug 21 05:44 PM
WILLIAM SIBOLD	Director	Aug 21 '25	Proposed Sale	391.66	7,616	2,982,883		Aug 21 04:24 PM
BAKER BROS. ADVISORS LP	Director	Aug 20 '25	Buy	385.16	59,901	23,071,366	1,947,968	Aug 20 06:12 PM
BAKER BROS. ADVISORS LP	Director	Aug 18 '25	Buy	373.21	37,164	13,869,831	1,893,120	Aug 20 06:12 PM
BAKER BROS. ADVISORS LP	Director	Aug 18 '25	Buy	364.04	68,618	24,979,827	1,859,091	Aug 20 06:09 PM
FRED CRAVES	Former Director	Aug 20 '25	Proposed Sale	390.22	1,000	390,224		Aug 20 04:12 PM
Kelley Shannon T	General Counsel	Aug 18 '25	Sale	367.81	1,304	479,627	9,173	Aug 18 05:33 PM
Shannon Kelley	Officer	Aug 18 '25	Proposed Sale	369.84	458	169,387		Aug 18 05:30 PM
FRED CRAVES	Former Director	Aug 18 '25	Proposed Sale	382.24	2,000	764,481		Aug 18 04:23 PM
BATE KENNETH	Director	Aug 15 '25	Option Exercise	16.46	10,000	164,600	12,627	Aug 15 06:04 PM
BATE KENNETH	Director	Aug 15 '25	Sale	365.20	10,000	3,652,009	2,627	Aug 15 06:04 PM
FRED CRAVES	Former Director	Aug 15 '25	Proposed Sale	366.70	4,100	1,503,481		Aug 15 05:34 PM
KENNETH M BATE	Director	Aug 15 '25	Proposed Sale	365.20	10,000	3,652,008		Aug 15 04:42 PM
FRIEDMAN PAUL A	Director	Aug 13 '25	Option Exercise	9.45	129,172	1,220,675	316,336	Aug 13 06:18 PM
FRIEDMAN PAUL A	Director	Aug 13 '25	Sale	370.24	129,172	47,825,149	187,164	Aug 13 06:18 PM
FRIEDMAN PAUL A	Director	Aug 12 '25	Option Exercise	9.45	43,605	412,067	230,769	Aug 13 05:45 PM
FRIEDMAN PAUL A	Director	Aug 11 '25	Option Exercise	9.45	3,203	30,268	190,367	Aug 13 05:45 PM
FRIEDMAN PAUL A	Director	Aug 12 '25	Sale	355.68	43,605	15,509,469	187,164	Aug 13 05:45 PM
FRIEDMAN PAUL A	Director	Aug 11 '25	Sale	350.27	3,203	1,121,917	187,164	Aug 13 05:45 PM
Taub Rebecca	Director	Aug 12 '25	Option Exercise	9.45	43,263	408,835	504,307	Aug 13 05:33 PM
Taub Rebecca	Director	Aug 11 '25	Option Exercise	9.45	3,200	30,240	464,244	Aug 13 05:33 PM
Taub Rebecca	Director	Aug 12 '25	Sale	355.69	43,263	15,388,279	461,044	Aug 13 05:33 PM
Taub Rebecca	Director	Aug 11 '25	Sale	350.24	3,200	1,120,753	461,044	Aug 13 05:33 PM
PAUL FRIEDMAN	Director	Aug 13 '25	Proposed Sale	359.00	129,172	46,372,748		Aug 13 04:22 PM
REBECCA TAUB	Director	Aug 12 '25	Proposed Sale	349.50	43,263	15,120,418		Aug 12 04:27 PM
PAUL FRIEDMAN	Director	Aug 12 '25	Proposed Sale	349.50	43,605	15,239,948		Aug 12 04:26 PM
PAUL FRIEDMAN	Director	Aug 11 '25	Proposed Sale	345.73	3,203	1,107,373		Aug 11 04:26 PM
REBECCA TAUB	Director	Aug 11 '25	Proposed Sale	345.73	3,200	1,106,336		Aug 11 04:26 PM
Taub Rebecca	Director	Jul 18 '25	Option Exercise	9.45	1,000	9,450	462,044	Jul 22 05:08 PM
Taub Rebecca	Director	Jul 18 '25	Sale	350.00	1,000	350,005	461,044	Jul 22 05:08 PM
FRIEDMAN PAUL A	Director	Jul 18 '25	Option Exercise	9.45	1,400	13,230	188,564	Jul 22 05:06 PM
FRIEDMAN PAUL A	Director	Jul 18 '25	Sale	350.03	1,400	490,044	187,164	Jul 22 05:06 PM
PAUL FRIEDMAN	Director	Jul 18 '25	Proposed Sale	348.73	1,400	488,222		Jul 18 05:25 PM
REBECCA TAUB	Director	Jul 18 '25	Proposed Sale	348.73	1,000	348,730		Jul 18 05:03 PM
FRIEDMAN PAUL A	Director	Jul 16 '25	Option Exercise	9.45	26,176	247,363	213,340	Jul 18 04:13 PM
FRIEDMAN PAUL A	Director	Jul 17 '25	Option Exercise	9.45	2,700	25,515	189,864	Jul 18 04:13 PM
FRIEDMAN PAUL A	Director	Jul 16 '25	Sale	353.47	26,176	9,252,543	187,164	Jul 18 04:13 PM
FRIEDMAN PAUL A	Director	Jul 17 '25	Sale	350.48	2,700	946,301	187,164	Jul 18 04:13 PM
Taub Rebecca	Director	Jul 16 '25	Option Exercise	9.45	26,444	249,896	487,488	Jul 18 04:11 PM
Taub Rebecca	Director	Jul 17 '25	Option Exercise	9.45	2,657	25,109	463,701	Jul 18 04:11 PM
Taub Rebecca	Director	Jul 16 '25	Sale	353.47	26,444	9,347,063	461,044	Jul 18 04:11 PM
Taub Rebecca	Director	Jul 17 '25	Sale	350.41	2,657	931,035	461,044	Jul 18 04:11 PM
REBECCA TAUB	Director	Jul 17 '25	Proposed Sale	344.97	2,657	916,585		Jul 17 04:21 PM
PAUL FRIEDMAN	Director	Jul 17 '25	Proposed Sale	344.97	2,700	931,419		Jul 17 04:20 PM
PAUL FRIEDMAN	Director	Jul 16 '25	Proposed Sale	311.14	26,176	8,144,401		Jul 16 04:20 PM
REBECCA TAUB	Director	Jul 16 '25	Proposed Sale	311.14	26,444	8,227,786		Jul 16 04:19 PM
CRAVES FRED B	Director	Mar 12 '25	Option Exercise	100.77	7,728	778,784	357,804	Mar 14 04:25 PM
CRAVES FRED B	Director	Mar 13 '25	Option Exercise	65.06	7,742	503,695	357,818	Mar 14 04:25 PM
CRAVES FRED B	Director	Mar 12 '25	Sale	331.84	7,728	2,564,426	350,076	Mar 14 04:25 PM
CRAVES FRED B	Director	Mar 13 '25	Sale	325.25	7,742	2,518,053	350,076	Mar 14 04:25 PM
FRED CRAVES	Director	Mar 13 '25	Proposed Sale	325.25	7,742	2,518,054		Mar 13 05:03 PM
Dier Mardi	SVP and CFO	Mar 10 '25	Sale	323.04	258	83,344	10,440	Mar 12 04:32 PM
FRED CRAVES	Director	Mar 12 '25	Proposed Sale	331.92	7,428	2,465,514		Mar 12 04:11 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Mar 05 '25	Option Exercise	87.49	14,113	1,234,766	17,841	Mar 07 05:40 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Mar 05 '25	Sale	341.32	14,113	4,817,104	3,728	Mar 07 05:40 PM
Kelley Shannon T	General Counsel	Mar 03 '25	Sale	335.00	415	139,025	7,290	Mar 05 04:36 PM

ACAD

Acadia Pharmaceuticals Inc

MDGL

Madrigal Pharmaceuticals Inc

Upgrade your FINVIZ experience